AI Article Synopsis
- * Among 294 patients, 27% had a specific mutation, and those treated with pembrolizumab alone showed better progression-free survival compared to those without the mutation.
- * The findings propose a potential link between the mutation status and treatment effectiveness with pembrolizumab, although results for overall survival were not statistically significant for all groups.
Article Abstract
This retrospective study aims to identify a possible predictive role of mutations in non-small-cell lung cancer in response to first-line pembrolizumab, either as monotherapy or combined with chemotherapy. Patients received pembrolizumab alone (n = 213) or associated with chemotherapy (n = 81). A mutation in the gene was detected in 27% of patients. In patients on pembrolizumab alone, median progression-free survival in -mutated cases was longer than in wild-type cases (11.3 vs 4.4 months; p = 0.019), whereas median overall survival did not reach statistical significance (22.1 vs 12.5 months; p = 0.119). Patients receiving chemo-immunotherapy with -positive tumors had a similar progression-free survival (9.7 vs 7.3 months; p = 0.435); overall survival data were immature. This study suggests a correlation between status and response to pembrolizumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2023-0952 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!